+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Macular Degeneration Treatment Market Global Market Report 2022

  • PDF Icon

    Report

  • 175 Pages
  • June 2022
  • Region: Global
  • The Business Research Company
  • ID: 5600306
Major players in the macular degeneration treatment market are Novartis AG, Bausch Health Companies Inc, Regenxbio Inc, F Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc, GlaxoSmithKline plc, Bayer AG, Neurotech Pharmaceuticals Inc, Ophthotech Corporation, StemCells Inc, Pfizer Inc, Santen Pharmaceuticals, Alimera Sciences Inc, Aerie Pharmaceutical Inc, Panoptica, Allergan Inc, Valeant Pharmaceuticals, and Rxi Pharmaceuticals.

The global macular degeneration treatment market is expected to grow from $7.55 billion in 2021 to $8.08 billion in 2022 at a compound annual growth rate (CAGR) of 7.04%. The growth is mainly due to the companies' resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $10.65 billion in 2026 at a CAGR of 7.15%.

The macular degeneration treatment market consists of sales of macular degeneration treatment by entities (organizations, sole traders, and partnerships) that are used to treat macular degeneration eye disease. Macula refers to the central portion of the retina, a light-sensitive layer of tissue at the backside of the eye. The macula is responsible for central vision. Degeneration of the macula, which affects the central part of the retina (the macula) and results in distortion or loss of central vision, occurs most commonly after the age of 60 and is referred to as age-related macular generation (AMD).Macular degeneration treatment helps to slow the disease and prevent severe loss of vision.

The main disease stages of the macular degeneration treatment market are early-stage AMD, intermediate AMD, and late-stage AMD. In early-stage AMD, the macula changes, with medium-sized drusen deposits and no pigment changes, but does not impact vision. Intermediate AMD is when vision may get blurry or wavy with large drusen or pigment changes. In late-stage AMD, the central vision fails completely, causing vision loss. The different types of macular degeneration treatment include wet macular degeneration and dry macular degeneration. The different routes of administration of macular degeneration treatment include oral, injectable, and others used by different end-users such as ambulatory surgical centers, ophthalmic clinics, and hospitals.

In 2021, North America will be the largest region in the macular degeneration treatment market. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

The increasing burden of retinal disorders is expected to propel the growth of the macular degeneration treatment market. Retinal disorders affect the vital tissue and affect the way individuals process visual information, leading to distorted or absent vision. According to a study done in Tanzania in 2020 about the prevalence of retinal diseases and associated risk factors, out of 1,007 people, the prevalence of vitreoretinal disorders was 22.8% (230/1,007). The study was conducted by OSLI Retina, which focuses solely on retinal diseases, surgery, and pharmacotherapy. The leading retinal diseases were age-related hypertensive macular scars (2.7%), retinopathy (4.5%), and degeneration (7.0%). According to the American Academy of Opthalmology, in 2050, an estimated 7.32 million people in the United States will have primary open-angle glaucoma, with the highest numbers among populations aged 70 to 79 years (32%), women (50%), and Hispanics (50%). The largest demographic group is Hispanic men. Therefore, the increasing burden of retinal disorders is driving the growth of the macular degeneration treatment market.

The development of advanced therapies is a key trend gaining popularity in the macular degeneration treatment market. Advanced therapy, including gene therapy, for the treatment of disease has seen development in recent years, particularly within the world of inherited retinal disease. For instance, in the year 2019, Spark Therapeutics, a USA-based gene therapy treatment company, developed Luxturna, which is a therapy designed to treat patients with mutations on a gene called RPE65, which encodes a retinal protein necessary for the eye in order to respond to light.

In September 2021, Novartis, a Swiss-based pharmaceutical company, acquired Arctos Medical for an undisclosed amount. The acquisition is expected to allow Novartis to find treatments for patients with vision loss and leverage the potential of optogenetics as the basis of successful therapeutics. Arctos Medical is a Switzerland-based developer of smart medical devices and gene therapy approaches for ophthalmological diseases for treating blindness.

The countries covered in the Macular Degeneration Treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.





This product will be delivered within 1-3 business days.
Frequently Asked Questions about the Global Macular Degeneration Treatment Market

What is the estimated value of the Global Macular Degeneration Treatment Market?

The Global Macular Degeneration Treatment Market was estimated to be valued at $8.08 billion in 2022.

What is the growth rate of the Global Macular Degeneration Treatment Market?

The growth rate of the Global Macular Degeneration Treatment Market is 7.1%, with an estimated value of $10.65 billion by 2026.

What is the forecasted size of the Global Macular Degeneration Treatment Market?

The Global Macular Degeneration Treatment Market is estimated to be worth $10.65 billion by 2026.

Who are the key companies in the Global Macular Degeneration Treatment Market?

Key companies in the Global Macular Degeneration Treatment Market include Novartis AG, Bausch Health Companies Inc., Regenxbio Inc., F Hoffmann, La Roche Ltd, Regeneron Pharmaceuticals Inc., GlaxoSmithKline plc, Bayer AG and Ophthotech Corporation.

Table of Contents

1. Executive Summary2. Macular Degeneration Treatment Market Characteristics3. Macular Degeneration Treatment Market Trends And Strategies4. Impact Of COVID-19 On Macular Degeneration Treatment
5. Macular Degeneration Treatment Market Size And Growth
5.1. Global Macular Degeneration Treatment Historic Market, 2016-2021, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Macular Degeneration Treatment Forecast Market, 2021-2026F, 2031F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market
6. Macular Degeneration Treatment Market Segmentation
6.1. Global Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Wet Macular Degeneration
  • Dry Macular Degeneration
6.2. Global Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Early-Stage AMD
  • Intermediate AMD
  • Late-Stage AMD
6.3. Global Macular Degeneration Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Oral
  • Injectable
  • Others
6.4. Global Macular Degeneration Treatment Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Ambulatory Surgical Centers
  • Ophthalmic Clinics
  • Hospitals

7. Macular Degeneration Treatment Market Regional And Country Analysis
7.1. Global Macular Degeneration Treatment Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
7.2. Global Macular Degeneration Treatment Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
8. Asia-Pacific Macular Degeneration Treatment Market
8.1. Asia-Pacific Macular Degeneration Treatment Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
8.3. Asia-Pacific Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
9. China Macular Degeneration Treatment Market
9.1. China Macular Degeneration Treatment Market Overview
9.2. China Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion
9.3. China Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion
10. India Macular Degeneration Treatment Market
10.1. India Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
10.2. India Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
11. Japan Macular Degeneration Treatment Market
11.1. Japan Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
11.2. Japan Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
12. Australia Macular Degeneration Treatment Market
12.1. Australia Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
12.2. Australia Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
13. Indonesia Macular Degeneration Treatment Market
13.1. Indonesia Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
13.2. Indonesia Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
14. South Korea Macular Degeneration Treatment Market
14.1. South Korea Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
14.2. South Korea Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
15. Western Europe Macular Degeneration Treatment Market
15.1. Western Europe Macular Degeneration Treatment Market Overview
15.2. Western Europe Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
15.3. Western Europe Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
16. UK Macular Degeneration Treatment Market
16.1. UK Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
16.2. UK Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
17. Germany Macular Degeneration Treatment Market
17.1. Germany Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
17.2. Germany Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
18. France Macular Degeneration Treatment Market
18.1. France Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
18.2. France Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
19. Eastern Europe Macular Degeneration Treatment Market
19.1. Eastern Europe Macular Degeneration Treatment Market Overview
19.2. Eastern Europe Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
19.3. Eastern Europe Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
20. Russia Macular Degeneration Treatment Market
20.1. Russia Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
20.2. Russia Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
21. North America Macular Degeneration Treatment Market
21.1. North America Macular Degeneration Treatment Market Overview
21.2. North America Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
21.3. North America Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
22. USA Macular Degeneration Treatment Market
22.1. USA Macular Degeneration Treatment Market Overview
22.2. USA Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
22.3. USA Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
23. South America Macular Degeneration Treatment Market
23.1. South America Macular Degeneration Treatment Market Overview
23.2. South America Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
23.3. South America Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
24. Brazil Macular Degeneration Treatment Market
24.1. Brazil Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
24.2. Brazil Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
25. Middle East Macular Degeneration Treatment Market
25.1. Middle East Macular Degeneration Treatment Market Overview
25.2. Middle East Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
25.3. Middle East Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
26. Africa Macular Degeneration Treatment Market
26.1. Africa Macular Degeneration Treatment Market Overview
26.2. Africa Macular Degeneration Treatment Market, Segmentation By Types, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
26.3. Africa Macular Degeneration Treatment Market, Segmentation By Stage of Disease, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
27. Macular Degeneration Treatment Market Competitive Landscape And Company Profiles
27.1. Macular Degeneration Treatment Market Competitive Landscape
27.2. Macular Degeneration Treatment Market Company Profiles
27.2.1. Novartis AG
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. Bausch Health Companies Inc
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. Regenxbio Inc
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. F Hoffmann-La Roche Ltd
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. Regeneron Pharmaceuticals Inc
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance
28. Key Mergers And Acquisitions In The Macular Degeneration Treatment Market29. Macular Degeneration Treatment Market Future Outlook and Potential Analysis
30. Appendix
30.1. Abbreviations
30.2. Currencies
30.3. Research Inquiries
30.4. About the Publisher
30.5. Copyright And Disclaimer

Executive Summary

Macular Degeneration Treatment Global Market Report 2022 provides the strategists, marketers and senior management with the critical information they need to assess the global Macular Degeneration Treatment Market.

This report focuses on Macular Degeneration Treatment Market which is experiencing strong growth. The report gives a guide to the Macular Degeneration Treatment Market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pandemic.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Description:

Where is the largest and fastest growing market for the macular degeneration treatment market? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Macular Degeneration Treatment Market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider Macular Degeneration Treatment Market, and compares it with other markets.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
  • The Macular Degeneration Treatment Market section of the report gives context. It compares the Macular Degeneration Treatment Market with other segments of the Macular Degeneration Treatment Market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, macular degeneration treatment market indicators comparison.

Scope


Markets Covered:

1) By Stage of Disease: Early-Stage AMD; Intermediate AMD; Late-Stage AMD
2) By End User: Ambulatory Surgical Centers; Ophthalmic Clinics; Hospitals
3) By Route of Administration: Oral; Injectable; Others
4) By Types: Wet Macular Degeneration, Dry Macular Degeneration

Companies Mentioned: Novartis AG; Bausch Health Companies Inc.; Regenxbio Inc.; F Hoffmann-La Roche Ltd.; Regeneron Pharmaceuticals Inc.

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Novartis AG
  • Bausch Health Companies Inc.
  • Regenxbio Inc.
  • F Hoffmann-La Roche Ltd
  • Regeneron Pharmaceuticals Inc.
  • GlaxoSmithKline plc
  • Bayer AG
  • Neurotech Pharmaceuticals Inc.
  • Ophthotech Corporation
  • Stemcells Inc.
  • Pfizer Inc.
  • Santen Pharmaceuticals
  • Alimera Sciences Inc.
  • Aerie Pharmaceutical Inc.
  • Panoptica
  • Allergan Inc.
  • Valeant Pharmaceuticals
  • Rxi Pharmaceuticals

Methodology

Loading
LOADING...